Avadel Pharmaceuticals (AVDL) Q3 2024 earnings summary

Executive summary

• Q3 2024 net product revenue reached $50 million, with 2,300 active LUMRYZ patients and 700 new starts, reflecting strong patient growth and market expansion.

• FDA approved LUMRYZ for pediatric narcolepsy, granting Orphan Drug Exclusivity through 2031 and expanding the eligible patient base.

• Court rulings affirmed FDA approval and clinical superiority for LUMRYZ, allowing continued sales despite ongoing litigation with Jazz Pharmaceuticals.

• Investments in patient engagement and support targeted persistency challenges, especially for new to oxybate patients.

• Phase 3 REVITALYZ trial for idiopathic hypersomnia is ongoing to expand indications.

Financial highlights

• Q3 2024 net revenue was $50 million, with gross profit of $43.9 million and gross margin of 87.7%–88%.

• Operating expenses for Q3 were $44.2 million, including $6.4 million in non-cash charges; cash, cash equivalents, and marketable securities totaled $65.8–$66 million at quarter end.

• Operating loss narrowed to $0.3 million from $35.1 million year-over-year.

• Net loss per share improved to $0.03 for Q3 2024.

• Net cash used in operations was $54.8 million for the nine months ended September 30, 2024.

Outlook and guidance

• Q4 expected to see seasonal impacts from fewer provider visits and higher gross-to-net deductions due to insurance resets.

• Recurring quarterly cash operating expenses projected at $40–$45 million, with non-cash expenses at $6–$7 million.

• Management expects continued growth in LUMRYZ demand, especially among new-to-oxybate and pediatric patients, with positive cash flow anticipated in Q4.

• Sufficient liquidity is expected for at least the next twelve months.

• Continued strong payer coverage anticipated into 2025, with Medicare coverage expected to expand.